Abstract Body

Background: Depression is a frequent comorbidity in HIV infection and an important predictor of poor treatment outcomes and increased mortality. Accumulating evidence suggests that inflammation and increased tryptophan catabolism are associated with increased risk of developing major depressive disorder in HIV infection, but the mechanisms leading to depression remain poorly understood.

Methods: The severity of depressive symptoms was assessed by Beck Depression Inventory or Center for Epidemiological Studies Depression Scale. Untargeted metabolomic profiling of plasma from 104 subjects across three independent cohorts (32 HIV+ subjects on ART from NNTC and CHARTER [median CD4 288 cells/ul, median plasma VL 50 copies/ml; n=15 and n=17 with and without depressive symptoms], 36 HIV+ [median CD4 350 cells/ul, median plasma VL 630 copies/ml; n=13 and n=23 with and without depressive symptoms] and 36 HIV- [n=12 and n=24 with and without depressive symptoms] subjects from ALIVE) was performed using liquid or gas chromatography followed by mass spectrometry to detect > 400 metabolites. Cytokine profiling was performed by Bioplex array. Bioinformatic analysis were performed in Metaboanalyst and R.

Results: Decreased monoamine metabolites of phenylalanine/tyrosine catabolism (phenylacetate and 4-hydroxyphenylacetate) and acylcarnitines (propionylcarnitine, isobutyrylcarnitine, isovalerylcarnitine, and 2-methylbutyrylcarnitine) in plasma distinguished between subjects with and without depressive symptoms in both HIV+ and HIV- cohorts (FC>1.2, p<0.05, FDR<10%), and these alterations correlated with the severity of depression. In HIV+ subjects, depressive symptoms were associated with augmented IFN responses (IFN-gamma, CXCL9, CXCL10) and tryptophan catabolism (increased kynurenine to tryptophan ratio), and these changes correlated with metabolite alterations associated with depression (p<0.05, FDR<10%). Altered metabolites mapped to pathways involved in monoamine metabolism, mitochondrial function, and inflammation, suggesting a model in which complex inter-relationships between monoamine metabolism and mitochondrial bioenergetics contribute to biological mechanisms involved in depression that may be augmented by inflammation during HIV infection.

Conclusions: Integrated approaches targeting inflammation, monoamine metabolism (tryptophan [serotonin], phenylalanine [dopamine], and trace amines), and mitochondrial pathways may be important for prevention and treatment of depression in people with and without HIV.